 Population-based incidence for RSE 3.0/100 000 and SRSE 0.6/100 000  48% recovered to baseline, 29% showed functional deficit, and 23% died at 1 year  21% of RSE patients developed SRSE  Older age and progressive/fatal etiologies predict poorer outcome  Anesthesia should be used only in RSE cases with reasonable long-term prognosis
Introduction
Status epilepticus (SE) is a condition resulting from the failure of the mechanisms responsible for seizure termination or from initiation mechanisms that lead to abnormally prolonged seizures . The morbidity and mortality of SE correlate with the duration of epileptic activity, rapid identification of the cause of SE, and age and comorbidity of the patients (Trinka and Kälviäinen, 2016) . SE becomes refractory (RSE) if first-and second-line treatments with antiepileptic drugs (AEDs) fail to terminate the seizure. SE is defined as super-refractory (SRSE) if it continues for more than 24 h after the first administration of general anesthesia (Shorvon and Ferlisi, 2012) .
The incidence in different European cohorts for SE (lasting over 30 min) is 10-16/100 000 (Coeytaux et al., 2000; Knake et al., 2001) . Population-based incidence data for RSE and SRSE are scarce. A recent hospital-based 9-year cohort study of RSE and SRSE from Switzerland suggests that 33% of SE becomes RSE and only 4% of SE becomes SRSE (Delaj et al., 2016) , resulting in incidence for RSE 3.3-5.3/100 000 and for SRSE 0.4-0.6/100 000. The highest incidence rate for RSE and SRSE was reported in the US:
7.2/100 000 for RSE (SE duration 2-24 h) and 4.6/100 000 for SRSE (SE duration >24 h); however, this definition was purely time-based (Hesdorffer et al., 1998) . We have recently reported the nationwide population-based incidence in Finland for RSE (SE treated in intensive care unit (ICU) with general anesthesia) 3/100 000 and for SRSE 0.7/100 000 (Kantanen et al., 2015) .
The underlying etiology of SE is considered the most important prognostic factor determining the overall outcome (Neligan and Shorvon, 2010; Sutter et al., 2013) . Both clinical studies and experimental data have shown that the longer the duration of SE before the initiation of treatment and the time required to control SE, the worse is the prognosis (Towne et al., 1994; Mazarati et al., 1998; Neligan and Shorvon, 2011) . The outcome of SE also varies with age, with the best outcomes in young children and the worst ones in the elderly. However, it is unclear whether age is a factor independent of etiology (Towne et al., 1994; Mazarati et al., 1998; Neligan and Shorvon, 2011) . Older age (>65 years), no seizure history, specific seizure types, and impaired consciousness together seem to predict a worse outcome (Sutter et al., 2013) . Other negative outcome predictors are the presence of acute brain lesions, infections, respiratory failure, or postictal periodic epileptiform discharges in electroencephalogram (EEG) signals (Neligan and Shorvon, 2010; Sutter et al., 2015) The long-term outcome of ICU-treated RSE has been poorly studied. In a comprehensive literature review (Shorvon and Ferlisi, 2012 ) through 1981 cases with RSE and treated with general anesthesia with variable long-term outcome data could be found.
Overall, 35% of the patients died, 30% showed neurological deficit, and 35% recovered to baseline. Between 2011 and Oct. 2016, we found 427 newly published cases (Table 1); however, this series is still small, follow-up times were variable, and the outcome seemed essentially unchanged. In the new series, for SRSE, 55% of patients died, 25% were impaired, and 20% recovered to baseline. No data is available for the predictors of the long-term outcome.The present study aims to determine the 1-year outcome of ICUtreated RSE and SRSE in a population-based study.
Methods

Patients
We retrospectively analyzed the Finnish Intensive Care Consortium (FICC) database to identify ICU-treated RSE patients in a population-based cohort from Kuopio University
Hospital's (KUH) special responsibility area in the middle and eastern part of Finland during a three-year-period (Jan. 1, 2010 to Dec. 31, 2012). KUH's catchment area consists of five hospitals-one university hospital and four central hospitals-that together provide ICU and acute neurological care to a population of 840 000 (Figure 1 ). We searched the FICC database by using the ICD-10 codes for epilepsy, SE, and convulsions (G40.x, G41.x, R58.6) and the Acute Physiology and Chronic Health Evaluation (APACHE) II (Knaus et al., 1985) diagnostic group "seizure" to identify all patients treated in an ICU for seizure disorders. We included all adult (>16 years) patients who were treated in the ICU for at least 48 h (approximate minimum duration of treatment for patients treated with general anesthesia in ICUs). The data was re-evaluated using medical records by an ICU physician or a neurologist in each hospital to identify RSE patients according to the study criteria. The diagnostic criteria for RSE was ICU-treated SE that showed recurrent or continuous seizure activity after first-and second-line AED treatments and that was treated with general anesthesia. We also identified patients meeting the criteria of SRSE (RSE continuing or recurring for more than 24 h after the first administration of general anesthesia (Reinikainen et al., 2012) . In addition to FICC-provided clinical data, we performed a retrospective medical record review for SE type, SE etiology, first-and second-line AEDs and intravenous anesthetics used, and long-term (1-year) outcomes.
The patient age and gender were obtained from the database. The SE type and seizure semiology were analyzed from the medical records using a clinical classification of SE types according to the seizure semiology and ILAE taxonomic criteria of prominent motor symptoms and impairment of consciousness . The etiology was categorized as the known cause (acute/remote/progressive symptomatic) SE defined in clinical electrophysiological syndromes and unknown (cryptogenic) ).
An acute symptomatic cause of SE was defined as SE within 7 days of an acute systemic or CNS insult (Beghi et al., 2010) .
Independence in activities of daily living (ADL) was coded as independent or dependent (with supervision, direction, or personal assistance) as a measure of patients' pre-morbid functional capacity. Sequential organ failure assessment (SOFA) (Vincent et al., 1998) was used as a prognostic outcome score describing ICU patients' severity of illness by different organ failures at the first 24 h: respiratory, cardiovascular, hepatic, coagulation, renal, and neurological systems. The Glasgow Coma Scale (GCS) (Teasdale and Jennet, 1974) for describing the impairment of consciousness was assessed at the time of ICU admission before any sedative medication was administered. The status epilepticus severity score (STESS) was calculated retrospectively using the GCS, seizure type at onset, age at onset, and history of seizures at onset (Rossetti et al., 2008) .
The time (in hours) from hospital admission to ICU admission was obtained from the database. The data on the availability of diagnostic EEG, continuous EEG monitoring during anesthesia, and of diagnostic EEG to confirm the cessation of refractory status after anesthesia was reviewed from the medical records. The frequency of propofol infusion syndrome (PRIS) and need for vasoactives were evaluated. The Length of stay (LOS) in the ICU and hospital (including ICU stay) were obtained from the FICC database. The hospital discharge status was defined in the FICC data as back to home, specialist care facility (other central hospital or rehabilitation center), or primary healthcare ward. A modified Rankin Scale (mRS) was used as the long-term (1-year) outcome measure (Bamford et al., 1989) : recovery to baseline (0-3); functional deficit (4-5); and dead (6).
The mRS outcome was assessed by using the best description available from the medical records and was classified as either good (mRS 0-3, recovered to baseline) or poor (mRS 4-6, major functional deficit or death).
Statistics
The population incidence with 95% CI was calculated for single incidence rate. Statistical analyses were conducted using SPSS software version 22 (IBM Corp, Armon, NY, USA)
The chi-square test and Fischer's exact test were used to compare the categorical variables, and non-parametric (Mann-Whitney U for median) tests were used with continuous variables. Binary logistic regression analysis was not performed owing to the relatively small sample size (n = 75).
Standard protocol approvals, registrations, and patient consents
We conducted a retrospective observational study based on the national ICU registry and medical records. Authorization for using the medical registry data was granted by the regulatory authority responsible for the administration of said data in Finland, namely, the respective hospital districts.
Results
3.1.
Incidence, mortality, and morbidity KUH catchment area ICUs had 14 261 admissions during 2010-2012. Figure 2 shows the data collection. Seventy-five patients (0.5% of all ICU admissions) with RSE fulfilling the criteria were treated at the ICUs in the KUH catchment area between January 2010 and December 2012. The annual incidence of RSE was 3.0/100 000 (95% confidence interval (CI) 2.4-3.8) and SRSE 0.6/100 000 (95% CI 0.4-1.0) in the cohort population.
The ICU mortality for the whole cohort (RSE) was 0%, hospital mortality was 7% (95% CI 1.2%-12.8%), and 1-year mortality was 23% (CI 95% 13.4%-32.5%). Thirty-six of the 75 (48%) patients recovered to baseline, and 22 (29%) showed neurological deficit at 1 year.
Poor outcome (mRS 4-6) was recorded for 39/75 (52%) patients. The hospital mortality for SRSE patients was 6% (n = 1) (95% CI 0%-17.6%), and 1-year mortality was 19% (n = 3) (95%CI 0%-38.2%). Figure 3 shows the functional outcome for RSE and SRSE.
3.2.
Demographics and predictors by 1-year outcome in RSE Table 2 shows the patients' demographics and clinical predictors for the whole RSE cohort and according to the functional outcome at 1 year. The median age of the patients was 56 years (range 18-82). Older age was associated with poorer outcome at 1 year (p = 0.03).
Focal onset evolving to bilateral convulsive SE was the most common seizure type (75%, 56/75) in patients; non-convulsive SE with coma accounted for 19% (14/75) of patients.
Baseline ADL functioning, seizure type, etiology category, STESS score, or variables indicating the duration of SE did not predict the outcome. 
Super-refractory status epilepticus
Sixteen patients of the cohort RSE (21%) were classified as SRSE patients. The median age was 51 (range 18-71), and 8 were male (50%). The etiology was remote symptomatic in 56% (9/16) of the cases (Table 5 ). Five (31%) patients had pre-existing epilepsy. Focal onset evolving to bilateral convulsive SE was the most common type of seizure in 12/16 (75%) patients. The median length of stay in the ICU was 8 days (range 4-12) and that in the hospital, 17 days (8-45 days). The second IV anesthetic used was thiopental 12 h in 10/16 (63%) patients, thiopental 24 h in 3/16 (19%), and propofol 24 h in 2/16 (13%).
Discussion
Main findings
To the best of our knowledge, this retrospective, population-based study of ICU-and anesthesia-treated RSE and SRSE patients is the largest cohort with 1-year functional outcome reported to date (Table 1) (Shorvon and Ferlisi, 2011) . Our 1-year outcome data agrees with the most recent series reporting long-term mortality rates of 26%-34% and with variable follow-up times of 1-12 months with overall poor functional outcome in 11-28 % of the patients (Table 1) . We can confirm that even with RSE treated with anesthesia in the ICU, half of the patients showed functional improvement over time and recovered by 1 year. This outcome was better than that of an earlier series published for 1981-2011 (Shorvon and Ferlisi, 2011) , in which only 30% of patients recovered.
Our short-term mortality rates are low, being 7% for RSE and 6% for SRSE; these are in agreement with the data from the Finnish national study we have published, which are 6%
for RSE and 10% for SRSE (Kantanen et al., 2015) , but considerably lower than recently published short-term mortality rates of 25% for RSE and 38% for SRSE that were reported in Switzerland (Delaj et al., 2016) . Delaj et al. (2016) suggested in their discussion that this difference might be due to mortality assessment performed before an early transfer to another hospital in the Finnish national study. The length of hospital stay in the present study in our RSE patients was median 14 days (range 5-61) and median 17 days (range 8-45), which gives a median of 14 days to assess hospital mortality; this does not differ considerably from another recent study reporting the length of hospital stay in RSE patients and a hospital mortality of 18% (Madzar et al., 2016) . Giovannini et al. (2015) reported mortality of 37% at 30 days. Hospital and short-term mortalities are indeed estimated at different time-points and are therefore difficult to compare. Our long-term mortality rate for SRSE patients is also low (19%) compared to other studies (Table 1. ) and to the Finnish national study, which showed 12-month mortality 36% for SRSE (Kantanen et al., 2015) . We believe that the reason for this might be purely the small sample size and random selection of less severe etiologies, however, it shows that the SRSE does not necessarily have a poorer outcome.
Poor outcome was associated with older age, although individual patients with higher age of up to 79 years could recover functionally after RSE. We could not confirm the recently shown predictive value of STESS, especially of scores >3, in predicting not only mortality after RSE but also functional outcome (Madzar et al., 2016) . We were also unable to confirm the positive predictive value of earlier epilepsy (Dodrill and Wilensky, 1990; Madzar et al., 2016) . The poor outcome in patients with preexisting epilepsy was related to remote symptomatic etiology like stroke or brain injury or to a progressive syndrome.
Therefore, although they were often indicative of better prognosis, earlier seizures and epilepsy did not always predict a favorable outcome.
Overall, the treatment response and outcome were strongly influenced by the underlying etiology (Neligan and Shorvon, 2010; Sutter et al., 2013) . We could identify the putative etiology in 97% of patients and could recognize specific progressive etiologies during the treatment process that would eventually cause death or poor outcome. In literatures, acute symptomatic etiology is the most common, being reported in up to 72% of cases (DeLorenzo et al., 1996; Coeytaux et al., 2000) , and its outcome is reported to be worse than that of other etiologies (DeLorenzo et al., 1996; Claassen et al., 2002; Logroscino et al., 2002; Rossetti et al., 2006; Delaj et al., 2016) . In our series, acute symptomatic etiology was not related to poorer outcome as a group. One of the most evident acute symptomatic etiologies for RSE in our population was alcohol-withdrawal-related seizures, in 17% of the patients, whereas in other studies of SE, it was 3%-13% (DeLorenzo et al., 1995; Trinka et al., 2012; Ferlisi et al., 2015; Rohracher et al., 2016) . Alcohol-withdrawalrelated RSE had a similar, but not poorer, prognosis to RSE in general, and this explains why acute symptomatic etiology was overall not associated with poorer outcome in our study.
We could not reliably measure the duration of SE and could therefore not show whether the duration of RSE had an impact on the functional outcome (Sutter et al., 2013) .
Regarding the delay of treatment, from our dataset, we could determine the time from emergency department (ED) admission to ICU admission and the time from hospital admission to ICU admission; it did not differ, and, in fact, it showed a trend of being shorter in patients with poor outcome. This seems to indicate that patients with more serious disorders and correspondingly unfavorable outcomes were recognized. The length of stay in the ICU, which might correlate to the duration of RSE, did not differ between patients with good and poor outcomes; however, in the poor outcome group, the range was larger, indicating cases with longer stay and duration of SE.
A staged protocol dividing diagnostics and therapy to early, established, refractory and super-refractory stages is the hallmark of current SE treatment (Trinka and Kälviäinen, 2016) . In the present study, the use of EEG, first-and second-line AEDs, and IV anesthetics was in good agreement with the current national guidelines In Finland (Kälviäinen et al., 2009 ); first-line treatment was already started out-of-hospital. On the other hand, individual cases showed a trend toward a poorer outcome, where it was not clear whether the protocol was followed or what AEDs were administered. The lower mortality rates may also reflect the quite rigorous adherence to the treatment protocol in our area, as adequate initial treatment has been shown to be associated with more rapid seizure cessation (Aranda et al., 2010) . Recently, it was also hypothesized that the policy of early and aggressive treatment may have led to an evident decrease in SE deaths in the UK and Wales during 2001 -2013 (Neligan and Walker, 2016 .
All of the de novo RSE patients treated at ICU were left with at least one antiepileptic drug after hospitalization. So they were thought to be at risk for further seizures and were diagnosed as having epilepsy. It is very difficult to estimate who really developed epilepsy and who would in fact been able to manage without further AED treatment. We do not have long-term follow-up data of these patients regarding the prognosis of their epilepsy.
Limitations and need for future work
A weakness of this study is the retrospective data collection of the otherwise comprehensive and population-based cohort. Our incidence rates are at the same level as the whole of Finland and Europe (Kantanen et al., 2015; Delaj et al., 2016) and lower than those in the US (Hesdorffer et al., 1998) . Our strength is the population-based ICU registry data and clear definition of RSE, which allows us to compare results with previous works.
We have been able to collect data of all adult patients whose RSE was treated with anesthesia; however, we do not exactly know whether the same criteria were used to treat RSE at each ICU in the five hospitals. In addition we have no data about those patients who may have had RSE but were not treated in ICU with anesthesia because of presumed futility of intensive care. We were not able to retrieve pediatric data reliably and therefore chlldren are excluded from the analyses. Retrospective data collection from medical records limits our understanding of the exact duration of SE and evaluation of the full extent of all possible prognostic factors including detailed EEG parameters. A recent study (Leitinger et al., 2015) has validated a new score (epidemiology-based mortality score in status epilepticus, EMSE) that takes into consideration the etiology, age, EEG patterns, and comorbidity to predict outcomes. This approach necessitates a prospective evaluation of the predictors by the treating physicians and capturing structured data in the medical records. Another approach is a global audit of the treatment of RSE (Ferlisi et al., 2015) , in which neurologists or intensivists prospectively enter patients who require general anesthesia to control SE.
Conclusions
During 1-year follow-up, nearly 50% of ICU-and anesthesia-treated RSE patients recovered to baseline function, 30% showed new functional defects, and 20% died. SRSE does not necessarily have a poorer outcome. The outcome is worse in older patients and in patients with progressive or fatal etiologies. SE should be treated with generalized anesthesia only in refractory cases with reasonable long-term prognosis and after failure of adequately used first-and second-line AEDs. 
